Laserfiche WebLink
, Docusign Envelope lD: 700826AD-3CE3-815C-8194-013EF364AA04 <br />n Offer counseling to individuals for their OUD/AUD if they are expected to remain in jail for longer than <br />one (1) month. Provide MOUD/MAUD regardless of the individual's willingness to participate in <br />counseling. <br />n There may be reasons an individualwill not continue MOUD/MAUD in the community, such as no <br />available treatment provider in the community to which the individual is released. lf,the individual will <br />not continue MOUD/MAUD in the community, the decision when or if to discontinue MOUD/MAUD prior <br />to release must be based on a mutually agreed-upon decision between the individual and the <br />prescriber and must consider factors, including but not limited to, the risks of opioid misuse or overdose <br />during incarceration, and the individual's willingness to receive a four-week (4-week) dose of an <br />exten-ded-release injectable buprenorphine just prior to release which will provide a safe, tapered <br />withdrawal. <br />3. RELEASE <br />Contractor must accomplish the following prior to each individual's release from jail: <br />n Complete release planning and reentry coordination as soon as possible after admission to ensure an <br />effective plan is in place prior to release, including in the event of an unexpected release of an <br />individualwho needs continued treatment and services. <br />tr Provide at leasttwo (2) doses of an opioid reversalagent.(e.g:, naloxone or Narcan@) and training on <br />how to administer the medication to all individuals with OUD. <br />tr Schedule the first community appointment with a treatment facility for continuation of MOUD or MAUD. <br />n Provide in hand, upon release, and at no cost to the individual, a sufficient number of doses of MOUD <br />and/or MAUD to bridge the individual untilthe scheduled MOUD/MAUD follow-up appointment at the <br />selected community treatment facility. <br />. lf an individual is on a long-acting injectable medication, the Contractor will ensure the timing of the <br />injectable medication ensures sustained treatment effect to bridge the individual to the scheduled <br />MOUD/MAUD follow-up appointment at the selected community treatment facility. <br />. lf an individual is at risk of being released directly from court, inform them prior to going to court that <br />they may request to be transported back to jail by staff to receive these medications prior to going <br />home. <br />. ln situations where a follow-up appointment upon release cannot be made, e.g., after-hours bail- <br />out, give the individual enough medication to last until the next available appointment at the <br />community treatment. lf the appointment date is unknown or cannot be reliably estimated, give the <br />individual a 30-day supply at minimum. <br />ln situations where medications cannot be provided upon release, e.9., unscheduled release at a <br />time when medical.staff are not present in jail, Contractor must ensure the following: <br />o The individual id,informed that they may either return to the jail in the morning to receive bridge <br />medications; or <br />o lf no medical staff are present the following day, call in a prescription for the same bridge <br />medication to a local pharmacy, at no cost to the individual. <br />Assist Medicaid-eligible individuals to sign up for Medicaid or assist individuals whose Medicaid <br />coverage has been terminated to reestablish coverage. <br />HCA Contract No. K5885-05 Page 12 of 13